DelveInsight’s, “Acinetobacter Infections Pipeline Insight, 2023,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Acinetobacter Infections pipeline landscape. It covers the Acinetobacter Infections pipeline drug profiles, including Acinetobacter Infections clinical trials and nonclinical stage products. It also covers the Acinetobacter Infections pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Acinetobacter Infections pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Acinetobacter Infections NDA approvals (if any), and product development activities comprising the technology, Acinetobacter Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Acinetobacter Infections Pipeline Report
- DelveInsight’s Acinetobacter Infections pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Acinetobacter Infections treatment.
- The leading Acinetobacter Infections Companies includes Entasis Therapeutics, Spero Therapeutics, Omnix Medical, ABAC Therapeutics, Venatorx Pharmaceuticals, Armata Pharmaceuticals, Technophage, SA, Aridis Pharmaceuticals, Forge Therapeutics, AiCuris, Wockhardt, Tetraphase Pharmaceuticals, Geom Therapeutics, and others.
- Promising Acinetobacter Infections Pipeline Therapies includes Sulbactam, Durlobactam, Colistin, TP-102, ETX2514, Sulbactam, Imipenem/Cilastatin, ETX2514, 14C-ETX2514, moxifloxacin, ETX2514SUL, and others.
- The Acinetobacter Infections companies and academics are working to assess challenges and seek opportunities that could influence Acinetobacter Infections R&D. The Acinetobacter Infections pipeline therapies under development are focused on novel approaches to treat/improve Acinetobacter Infections.
To explore more information on the latest breakthroughs in the Acinetobacter Infections Pipeline treatment landscape of the report, click here @ Acinetobacter Infections Pipeline Outlook
Acinetobacter Infections Overview
Acinetobacter are gram-negative aerobic bacilli or coccobacilli that belong to the family Moraxellaceae.They are ubiquitous and can survive on dry surfaces for up to a month and are commonly carried on the skin of health care workers, increasing the likelihood of patients being colonized and medical equipment being contaminated. There are many species of Acinetobacter; all can cause human disease, but Acinetobacter baumannii (AB) accounts for about 80% of infections. Acinetobacter easily colonize tracheostomy sites and can cause community-acquired bronchiolitis and tracheobronchitis in healthy children and tracheobronchitis in immunocompromised adults.Hospital-acquired Acinetobacter pneumonias are frequently multilobar and complicated. Secondary bacteremia and septic shock are associated with a poor prognosis.
Acinetobacter Infections Emerging Drugs Profile
- Sulbactam-durlobactam: Entasis Therapeutics
Durlobactam (DUR; previously designated ETX2514) is a novel, broad-spectrum and potent inhibitor of Class A, C, and D β-lactamases. Sulbactam (SUL) is a β-lactam antibiotic with activity against Acinetobacter baumannii; however, β-lactamase-mediated resistance to sulbactam is now widespread rendering it generally ineffective. In preclinical studies, durlobactam inhibits the β-lactamases commonly found in A. baumannii thus restoring sulbactam’s activity. The company is developing SUL-DUR (previously designated ETX2514SUL), a combination of β-lactam antibiotic and a β-lactamase inhibitor for the treatment of serious infections cuased by Acinetobacter, including multidrug-resistant (MDR) strains. In October 2021 the company announced positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant ABC infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. SUL-DUR has been designated a Qualified Infectious Disease Product (QIDP) by the U.S. Food and Drug Administration and awarded Fast Track status.
For further information, refer to the detailed Acinetobacter Infections Unmet Needs, Acinetobacter Infections Market Drivers, and Acinetobacter Infections Market Barriers, click here for Acinetobacter Infections Ongoing Clinical Trial Analysis
Acinetobacter Infections Pipeline Therapeutics Analysis
There are approx. 25+ key companies which are developing the therapies for Acinetobacter Infections. The companies which have their Acinetobacter Infections drug candidates in the most advanced stage, i.e. phase III include, Entasis Therapeutics.
Acinetobacter Infections Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Request a sample and discover the recent advances in Acinetobacter Infections Ongoing Clinical Trial Analysis and Medications, click here @ Acinetobacter Infections Treatment Landscape
Scope of the Acinetobacter Infections Pipeline Insight Report
- Coverage- Global
- Acinetobacter InfectionsCompanies- Entasis Therapeutics, Spero Therapeutics, Omnix Medical, ABAC Therapeutics, Venatorx Pharmaceuticals, Armata Pharmaceuticals, Technophage, SA, Aridis Pharmaceuticals, Forge Therapeutics, AiCuris, Wockhardt, Tetraphase Pharmaceuticals, Geom Therapeutics, and othersf
- Acinetobacter InfectionsPipeline Therapies- Sulbactam, Durlobactam, Colistin, TP-102, ETX2514, Sulbactam, Imipenem/Cilastatin, ETX2514, 14C-ETX2514, moxifloxacin, ETX2514SUL, and others.
- Acinetobacter Infections Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action
Dive deep into rich insights for drugs for Acinetobacter Infections Market Drivers and Acinetobacter Infections Market Barriers, click here @ Acinetobacter Infections Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Acinetobacter Infections: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Acinetobacter Infections – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Acinetobacter Infections Collaboration Deals
- Late Stage Products (Phase III)
- Sulbactam-durlobactam: Entasis Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- SPR 206: Spero Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Acinetobacter Infections Key Companies
- Acinetobacter Infections Key Products
- Acinetobacter Infections- Unmet Needs
- Acinetobacter Infections- Market Drivers and Barriers
- Acinetobacter Infections- Future Perspectives and Conclusion
- Acinetobacter Infections Analyst Views
- Acinetobacter Infections Key Companies
- Appendix
Got Queries? Find out the related information on Acinetobacter Infections Mergers and acquisitions, Acinetobacter Infections Licensing Activities @ Acinetobacter Infections Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services